Stefania Mazzalai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Stefania Mazzalai has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Aleksandra Zeljkovic
Department of Medical Biochemistry, University of Belgrade-Faculty of Pharmacy, 11000 Belgrade, Serbia
1 shared publication - Jelena Vekic
Department of Medical Biochemistry, University of Belgrade-Faculty of Pharmacy, Belgrade, Serbia
1 shared publication - Juan Gambini
Department of Physiology, Faculty of Medicine and Dentistry, University of Valencia, Av. de Blasco Ibáñez, 15, 46010 Valencia, Spain
1 shared publication - Kristine Stromsnes
Freshage Research Group, Department of Physiology, Faculty of Medicine, Institute of Health Research-INCLIVA, University of Valencia and CIBERFES, 46010 Valencia, Spain
1 shared publication - Manfredi Rizzo
RAK College of Pharmacy, RAK Medical and Health Sciences University, Ras Al Khaimah 11172, United Arab Emirates
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 26 October 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (11) , 2897
Oxidative Stress, Atherogenic Dyslipidemia, and Cardiovascular Risk
Oxidative stress is the consequence of an overproduction of reactive oxygen species (ROS) that exceeds the antioxidant defense mechanisms. Increased levels of ROS contribute to the development of cardiovascular disorders through oxidative damage to macromolecules, particularly by oxidation of plasma lipoproteins. One of the most prominent features of atherogenic dyslipidemia is plasma accumulation of small dense LDL (sdLDL) particles, characterized by an increased susceptibility to oxidation. Indeed, a considerable and diverse body of evidence from animal models and epidemiological studies was generated supporting oxidative modification of sdLDL particles as the earliest event in atherogenesis. Lipid peroxidation of LDL particles results in the formation of various bioactive species that contribute to the atherosclerotic process through different pathophysiological mechanisms, including foam cell formation, direct detrimental effects, and receptor-mediated activation of pro-inflammatory signaling pathways. In this paper, we will discuss recent data on the pathophysiological role of oxidative stress and atherogenic dyslipidemia and their interplay in the development of atherosclerosis. In addition, a special focus will be placed on the clinical applicability of novel, promising biomarkers of these processes.
- 26 October 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (11) , 2897
Top Cited PapersOpen AccessOxidative Stress, Atherogenic Dyslipidemia, and Cardiovascular Risk
Oxidative stress is the consequence of an overproduction of reactive oxygen species (ROS) that exceeds the antioxidant defense mechanisms. Increased levels of ROS contribute to the development of cardiovascular disorders through oxidative damage to macromolecules, particularly by oxidation of plasma lipoproteins. One of the most prominent features of atherogenic dyslipidemia is plasma accumulation of small dense LDL (sdLDL) particles, characterized by an increased susceptibility to oxidation. Indeed, a considerable and diverse body of evidence from animal models and epidemiological studies was generated supporting oxidative modification of sdLDL particles as the earliest event in atherogenesis. Lipid peroxidation of LDL particles results in the formation of various bioactive species that contribute to the atherosclerotic process through different pathophysiological mechanisms, including foam cell formation, direct detrimental effects, and receptor-mediated activation of pro-inflammatory signaling pathways. In this paper, we will discuss recent data on the pathophysiological role of oxidative stress and atherogenic dyslipidemia and their interplay in the development of atherosclerosis. In addition, a special focus will be placed on the clinical applicability of novel, promising biomarkers of these processes.